Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination;Amelioration du controle des nausees et vomissements lors d'une chimiotherapie moderement emetisante, par l'association ondansetron methylprednisolone et lorazepam, chez des patients en echec d'une association antiemetique anterieure

Bulletin du Cancer

Volumn 87, Issue 6, 2000, Pages 491-497

  Harousseau, Jean Luc ^a   Zittoun, Robert ^b   Bonneterre, Jacques ^c   Hedouin, Martine ^d   Ouvry, Jérôme ^d  

^a HÔTEL DIEU   (France)

^b HÔTEL DIEU   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d Laboratoire Glaxo Wellcome   (France)

Author keywords

Chemotherapy; Emesis; Iorazepam; Methylprednisolone; Ondansetron

Indexed keywords

LORAZEPAM; METHYLPREDNISOLONE; ONDANSETRON; SEROTONIN ANTAGONIST; ANTIEMETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VOMITING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; MIDDLE AGED; PATIENT SATISFACTION;

ADULT; ANTIEMETICS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LORAZEPAM; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NAUSEA; ONDANSETRON; PATIENT SATISFACTION; QUALITY OF LIFE; VOMITING;

EID: 0034200683     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. 1. Gralla RJ. Approaches to management of nausea and vomiting in the clinical setting. Clinician 1988 ; 6 : 26-38.
2. 2. Chevallier B. A compatison of two dose levels of granisetron in patients receiving high-dose cisplatin. The granisetron study group. Eur J Cancer 1990 ; 26 (suppl. 1) : S33-S6.
3. 3. Lebeau B, Depierre A, d'Allens H et le groupe pneumologique français d'étude de l'ondansétron. Efficacité antiémétique de l'ondansétron : comparaison randomisée avec l'association alizapride-méthylprednisolone dans les cancers bronchiques traités par cisplatine. Sem Hôp Paris 1991 ; 28-29 : 1350-7.
4. 4. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, et al. Comparison of the 5-hydroxytryptamine, (serotonin) antagonist ondansetron (GR 38032F) with high dose metoclopramide in the control of cisplatin-induced emesis. N Eng J Med 1990 ; 322 : 816-21.
5. 5. Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, et al. A randomised double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990 ; 8 : 1063-9.
6. 6. Chevallier B, Marty M, Paillarse JM, et le groupe de l'ondansétron. Association ondansétron et corticoïde dans les nausées er vomissements aigus et retardés induits par le cisplatine : évaluation sur trois cures successives. Cah Oncol 1993 ; 2 : 195-200.
7. 7. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis : a double-blind multicenrer randomised crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991 ; 9 : 675-8.
8. 8. Smith DB, Newlands ES, Rustin GJS, Begent RHJ, Howells N, McQuade B, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin containing chemotherapy. Lancet 1991 ; 338 : 487-90.
9. 9. Italian Group for Antiemetic Research. Ondansetron + dexamethasone versus metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 1992 ; 340 : 96-9.
10. 10. Gonzalez-Baron M, Chacon JI, Garcia-Giron C, Ordonez Gallego A, Garcia de Paredes ML, Feliu J, et al. Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy: a randomised trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam. Acta Oncol 1991 ; 30 : 623-7.
11. 11. Grunberg SM. Potential for combination therapy with the new anti-serotoninergic agents. Eur J Cancer 1993 ; 29A : S39-41.
12. 12. Kris MG, Baltzer L, Pisters KMW, Tyson LB. Enhancing the effectiveness of the specific serotonin antagonists. Cancer 1993 ; 72 : 3436-42.
13. 13. Navari RM, Province WS, Perrine GM, Kilgore JR. Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. Cancer 1993 ; 72 : 583-6.
14. 14. Laszlo J, Lucas VS. Emesis as a critical point in chemotherapy. N Engl J Med 1981 ; 305 : 948-9.
15. 15. Dilly S. Are granisetron and Ondansetron equivalent in the Clinic ? Eur J Cancer 1992 ; 28A (suppl. 1) : S32-5.
16. 16. Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994 ; 74 : 1945-52.
17. 17. Stewart A, McQuade B, Cronje JD, Goedhals L, Gudgeon A, Corette L, et al. Ondansetron compared with granisetron in the prophylaxis of against cyclophosphamide-induced emesis in out-patients. Oncology 1995 ; 52: 202-10.
18. 18. Lebeau B, Depierre A, Giovannini M, Riviere A, Kaluzinski J, Votan B, et al. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. Ann Oncol 1997 ; 8 : 887-92.
19. 19. Joseph A, Chicoye A, Bonneterre J. Un outil d'évaluation de la qualité de vie. In : Société française d'évaluation des soins et des technologies (Sofestec), et institut Gustave-Roussy, eds. Journée d'études. Les outils de l'évaluation en cancérologie : aspects méthodologiques. Villejuif 27 avril 1992 ; 31-6.
20. 20. Richard A, Lee J. Using multinational clinical trial data for psychometric evaluations : item reduction of the functional living index emesis. Quality of Life Research 1994 ; 3 : 54-5.
21. 21. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients : the functional living index-cancer ; development and validation. J Clin Oncol 1984 ; 2 : 472-83.